Short-term outcomes of Solaris self-expanding covered stent in iliac artery occlusive disease: a single-center retrospective cohort.

PURPOSE: Endovascular therapy is the preferred treatment for most iliac artery lesions; however, outcomes in complex TransAtlantic Inter-Society Consensus II (TASC) C-D anatomy remain less consistent than in simpler disease. This study evaluated the short-term clinical and patency outcomes of the Solaris self-expanding covered stent in a real-world cohort of patients with iliac artery disease. METHODS: This single-center retrospective study included 99 consecutive patients (140 iliac arteries) treated with the Solaris self-expanding covered stent between October 2023 and December 2025. Demographic, lesion, procedural, and follow-up data were analyzed. Primary patency was estimated using the Kaplan-Meier method, and TASC A-B and TASC C-D lesions were compared using the log-rank test. RESULTS: The mean age was 63.4 ± 9.8 years, 82.8% of patients were men, and TASC C-D lesions accounted for 55.7% of treated arteries. A total of 184 covered stents were implanted, and technical success was 100%. Median follow-up was 278 days (range, 32-576 days). Estimated Kaplan-Meier primary patency was 100% at 6 months and 97.6% at 12 months, with no significant difference between TASC A-B and TASC C-D lesions (log-rank P = 0.206). Complete clinical improvement (Rutherford category 0) was achieved in 80.8% of patients, and 96.0% improved by at least one Rutherford category. Procedure-related complications were infrequent, and no procedure-related deaths occurred. CONCLUSION: In a real-world cohort with a high proportion of complex iliac lesions, the Solaris self-expanding covered stent demonstrated excellent technical success, durable short-term patency, and favorable clinical outcomes. CLINICAL SIGNIFICANCE: The Solaris self-expanding covered stent demonstrated high technical success, excellent 12-month patency, and meaningful symptom improvement in patients with iliac artery occlusive disease, including a substantial proportion of complex TASC C-D lesions. These real-world findings suggest that this device may provide a durable endovascular solution for challenging iliac anatomy while maintaining a favorable safety profile.